

InnoVenture Iowa, LLC
Investment Committee Meeting
Wednesday, October 25th, 2023
6:00 am

Public Webinar Access:

<https://us02web.zoom.us/j/81228111828?pwd=ZlJtTStaQ3lmMjF0ay91VUxnZWtuUT09>

I. Committee Chair

Martina Bockenstedt

- A. Welcome
- B. Roll Call

II. Public Comment Period

A public comment period for the full meeting will be held at this time to accommodate visitors. This period is limited to 10 minutes.

Closed Session [Iowa Code sections 15.118, 21.5(1)a and 22.7]**

Discussion of Information Contained in Startup Due Diligence Process

III. CoCo Coders

Elizabeth Tweedale

- A. Founder Presentation
- B. Founder Q&A
- C. Internal Discussion

Discussion

IV. PVpallet

Philip Schwarz

- A. Founder Presentation
- B. Founder Q&A
- C. Internal Discussion

Discussion

Open Session [Iowa Code sections 15.118, 21.5(1)a and 22.7]**

Reopen Meeting for Formal Adjournment

V. Vote

Action

VI. Adjourn

Action

INNOVENTURE IOWA, LLC
666 Walnut Street, Suite 1285
Des Moines, Iowa 50309
Phone: (515) 657-7138



Investment Committee Members:

Martina Bockenstedt, Anita Norian, Leigh Parker

Non-Voting Attendees:

Kaylee Williams – Investment Director, Steve Brody – CEO, BioConnect Iowa, Philip Schwarz – Pvpallet, Elizabeth Tweedale – Coco Coders

Please Note:

The meeting will convene no earlier than stated above, but may begin later, depending on the length of earlier meetings. Agenda items may be considered out of order at the discretion of the Chair for each meeting. If you require accommodation to participate in this public meeting, call (515) 657-7138 to make your request. Please notify us as soon as possible in advance of the meeting.

****The InnoVenture Iowa Investment Committee**, if a quorum is present, may go into closed session pursuant to Iowa Code sections 21.5(1)a, 15.118, 22.7.3, 22.7.6 and 22.7.8 to review and discuss records InnoVenture Iowa is required to treat as confidential under Iowa law. This includes confidential business and financial information about applicants and industrial prospects with which the Fund is currently negotiating.